Differential expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines

Cytometry Part A

Volumn 81 A, Issue 12, 2012, Pages 1084-1091

  Lobba, A R M ^a   Forni, M F ^a   Carreira, A C O ^a   Sogayar, M C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast cancer; Breast cancer stem cell; Cancer stem cell; CD14; CD90; Thy 1

Indexed keywords

CD14 ANTIGEN; MESSENGER RNA; THY 1 ANTIGEN; TUMOR MARKER;

ARTICLE; BREAST TUMOR; CANCER STEM CELL; CELL STRAIN MCF 7; CHEMISTRY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METASTASIS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD14; ANTIGENS, THY-1; BREAST NEOPLASMS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84869877735     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.22220     Document Type: Article

References (44)

1. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion-Migrating cancer stem cells-An integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5: 744-749.
2. Shipitsin M, Polyak K. The cancer stem cell hypothesis: In search of definitions, markers, and relevance. Lab Invest 2008; 88: 459-463.
3. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010; 28: 4006-4012.
4. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010; 120: 41-50.
5. Krishan A, Ganjei-Azar P, Hamelik R, Sharma D, Reis I, Nadji M. Flow immunocytochemistry of marker expression in cells from body cavity fluids. Cytometry A 2010; 77A: 132-143.
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
7. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
8. + tumor cells in invasive breast carcinomas. Hum Pathol 2008; 39: 1096-1102.
9. + phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Res Treat 2012; 133: 979-995.
10. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005; 11: 1154-1159.
11. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
12. Soule HD, Maloney TM, Wolman SR, Peterson WDJr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial-cell line, Mcf-10. Cancer Res 1990; 50: 6075-6086.
13. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
14. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 1;29: e45.
15. Lee JA, Spidlen J, Boyce K, Cai J, Crosbie N, Dalphin M, et al. MIFlowCyt: The minimum information about a flow cytometry experiment. Cytometry A 2008; 73A: 926-930.
16. Assoian RK, Yin LQ, Castagnino P. ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. Cancer Res 2008; 68: 800-807.
17. Brown PO, Ross DT, Scherf U, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24: 227-235.
18. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527.
19. Williams AF, Gagnon J. Neuronal cell Thy-1 glycoprotein-Homology with immunoglobulin. Science 1982; 216: 696-703.
20. Seki T, Spurr N, Obata F, Goyert S, Goodfellow P, Silver J. The human Thy-1 gene-Structure and chromosomal location. Proc Natl Acad Sci U S A 1985; 82: 6657-6661.
21. Haeryfar SMM, Hoskin DW. Thy-1: More than a mouse pan-T cell marker. J Immunol 2004; 173: 3581-3588.
22. Craig W, Kay R, Cutler RL, Lansdorp PM. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 1993; 177: 1331-1342.
23. Barboni E, Gormley AM, Pliego Rivero FB, Vidal M, Morris RJ. Activation of T lymphocytes by cross-linking of glycophospholipid-anchored Thy-1 mobilizes separate pools of intracellular second messengers to those induced by the antigen-receptor/CD3 complex. Immunology 1991; 72: 457-463.
24. Tiveron MC, Barboni E, Pliego Rivero FB, Gormley AM, Seeley PJ, Grosveld F, Morris R. Selective inhibition of neurite outgrowth on mature astrocytes by Thy-1 glycoprotein. Nature 1992; 355: 745-748.
25. Fujita N, Kato Y, Naito M, Tsuruo T. A novel anti-Thy-1 (CD90) monoclonal antibody induces apoptosis in mouse malignant T-lymphoma cells in spite of inducing bcl-2 expression. Int J Cancer 1996; 66: 544-550.
26. Saalbach A, Hildebrandt G, Haustein UF, Anderegg U. The Thy-1/Thy-1 ligand interaction is involved in binding of melanoma cells to activated Thy-1-positive microvascular endothelial cells. Microvasc Res 2002; 64: 86-93.
27. He HT, Naquet P, Caillol D, Pierres M. Thy-1 supports adhesion of mouse thymocytes to thymic epithelial-cells through a Ca2(+)-independent mechanism. J Exp Med 1991; 173: 515-518.
28. Lung HL, Bangarusamy DK, Xie D, Cheung AK, Cheng Y, Kumaran MK, Miller L, Liu ET, Guan XY, Sham JS, et al. THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene 2005; 24: 6525-6532.
29. Abeysinghe HR, Pollock SJ, Guckert NL, Veyberman Y, Keng P, Halterman M, Federoff HJ, Rosenblatt JP, Wang N. The role of the THY1 gene in human ovarian cancer suppression based on transfection studies. Cancer Genet Cytogen 2004; 149: 1-10.
30. Fries KM, Blieden T, Looney RJ, Sempowski GD, Silvera MR, Willis RA, Phipps RP. Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin Immunol Immunopathol 1994; 72: 283-292.
31. Hagood JS, Mangalwadi A, Guo BL, MacEwen MW, Salazar L, Fuller GM. Concordant and discordant interleukin-1-mediated signaling in lung fibroblast Thy-1 subpopulations. Am J Respir Cell Mol Biol 2002; 26: 702-708.
32. Barker TH, Grenett HE, MacEwen MW, Tilden SG, Fuller GM, Settleman J, Woods A, Murphy-Ullrich J, Hagood JS. Thy-1 regulates fibroblast focal adhesions, cytoskeletal organization and migration through modulation of p190 RhoGAP and Rho GTPase activity. Exp Cell Res 2004; 295: 488-496.
33. Lázaro CA, Croager EJ, Mitchell C, Campbell JS, Yu C, Foraker J, Rhim JA, Yeoh GC, Fausto N. Establishment, characterization, and long-term maintenance of cultures of human fetal hepatocytes. Hepatology 2003; 38: 1095-1106.
34. Herrera MB, Bruno S, Buttiglieri S, Tetta C, Gatti S, Deregibus MC, Bussolati B, Camussi G. Isolation and characterization of a stem cell population from adult human liver. Stem Cells 2006; 24: 2840-2850.
35. Dan YY, Riehle KJ, Lazaro C, Teoh N, Haque J, Campbell JS, Fausto N. Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci USA 2006; 103: 9912-9917.
36. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST. Significance of CD90(+) cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-166.
37. Liu GT, Yuan XP, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CDI33(+) cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
38. True LD, Zhang H, Ye ML, Huang CY, Nelson PS, von Haller PD, Tjoelker LW, Kim JS, Qian WJ, Smith RD, et al. CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Mod Pathol 2010; 23: 1346-1356.
39. Cho RW, Wang XH, Diehn M, Shedden K, Chen GY, Sherlock G, Gurney A, Lewicki J, Clarke MF. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 2008; 26: 364-371.
40. Donnenberg VS, Donnenberg AD, Zimmerlin L, Landreneau RJ, Bhargava R, Wetzel RA, Basse P, Brufsky AM. Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry Part B Clin Cytom 2010; 78B: 287-301.
41. Setoguchi M, Nasu N, Yoshida S, Higuchi Y, Akizuki S, Yamamoto S. Mouse and human CD14 (myeloid cell-specific leucine-rich glycoprotein) primary structure deduced from cDNA clones. Biochim Biophys Acta 1989; 1008: 213-222.
42. Simmons DL, Tan S, Tenen DG, Nicholsonweller A, Seed B. Monocyte antigen CD14 is a phospholipid anchored membrane-protein. Blood 1989; 73: 284-289.
43. Stingl J. Detection and analysis of mammary gland stem cells. J Pathol 2009; 217: 229-241.
44. Kendrick H, Regan JL, Magnay FA, Grigoriadis A, Mitsopoulos C, Zvelebil M, Smalley MJ. Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 2008; 9: 591.